AXL INHIBITOR – AB801

AXL is a receptor tyrosine kinase that is expressed in a variety of tumors and is correlated with poor prognosis. AXL signaling mediates therapeutic resistance to multiple standard-of-care therapies and creates an immunosuppressive tumor microenvironment.

AB801 is an investigational AXL inhibitor. By inhibiting AXL signaling, AB801 may allow tumors to overcome AXL-mediated resistance and reignite responses to standard-of-care therapies.